Novartis (NVS) Stock: Buy, Sell, or Hold?
NVS - Novartis AG
$141.00
-0.05 (-0.04%)
▼
5d:
-3.07%
30d:
-13.21%
90d:
-9.32%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
23d
Get Alerted When NVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NVS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$218.19
Based on 7.6% avg growth
INTRINSIC VALUE TODAY
$135.48
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVS is currently trading at $141.00, which is considered slightly low relative to its 30-day fair value range of $138.15 to $155.74. The stock's valuation (Forward PE: 14.3) is in line with its historical norms (15.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVS is in a uptrend. The price is currently testing key support at $139.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NVS scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $156.29 (+10.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVS is in a uptrend. The price is currently testing key support at $139.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NVS scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $156.29 (+10.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$138.15 -
$155.74
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($156.29)
- CAUTION: Bottoming setup, but lagging the sector by 28% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$138.15 -
$155.74
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$139.95
Resistance Level
$147.03
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.33
Wall Street Target
$156.29
(+10.8%)
Revenue Growth (YoY)
0.8%
Earnings Growth (YoY)
-17.0%
Profit Margin
22.5%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
14.3 vs 15.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$137.62
(-2%)
2-Year Target
$134.31
(-5%)
3-Year Target
$131.09
(-7%)
3-Yr Target (if PE normalizes)
(PE: 14→15)
$140.84
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 11.2%)
$275.76
(+96%)
Base:
(SPY PE: 14.3, Growth: 11.2%)
$193.76
(+37%)
Bear:
(PE: 12.2, Growth: 11.2%)
$164.69
(+17%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 21.31 | Current EPS (TTM): $6.62
Bull Case
$230.55
(+64%)
Analyst growth 48.6%, PE expands to 23.4
Base Case
$209.60
(+49%)
Market implied 48.6%, PE stable at 21.3
Bear Case
$95.91
(-32%)
Severe decline -20.0%, PE contracts to 18.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.3 to 15.4
Stabilization Target:
$151.49
(+7.4%)
PE Expansion Potential:
+7.4%
Share & Embed Analysis
Last updated: October 02, 2026 7:41 PM ET
Data refreshes hourly during market hours. Next update: 8:41 PM
Data refreshes hourly during market hours. Next update: 8:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1325 | 48 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$159 | 46 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$279 | 57 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$389 | 55 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$238 | 48 HOLD |
